

You Can Make New Treatments Possible

WE NEED YOU TO PARTICIPATE IN CLINICAL TRIALS

TRIAL NAME (sponsor)	PATIENT DIAGNOSIS	AGE RANGE	DRUG/ COMPOUND	EGFR IN ML/MIN
DUPLEX (Retrophin)	FSGS	8-75	Sparsentan	≥ 30
THE PODO TRIAL (Pfizer)	FSGS	18+	PF- 06730512	≥ 30
PODOCYTE STUDY (Mallinckrodt)	FSGS	18+	Acthar	≥ 30
AURONA (Aurinia)	FSGS	18-75	Voclosporin	> 30
LUMINA STUDIES (ChemoCentryx)	FSGS	18+	CCX140-B	> 30
FIRSTx (Complexa)	FSGS	18+	CXA-10	≥ 40
LIPOSORBER LA-15 SYSTEM FOR CHILDREN WITH FSGS (Kaneka)	Post-transplant recurrent FSGS or Primary FSGS	5+	Liposorber LA-15 System	≥ 60 or post-trans- plant recurrence
PHOENIX TRIAL (ENROLLMENT COMPLETE) (Reata)	FSGS or IgAN	18-65	Bardoxolone methyl	≥ 30
EFFICACY & SAFETY OF BLESELUMAB TO PREVENT RECURRENCE (Astellas)	De novo transplant due to FSGS	18+	Bleselumab (added to SOC)	N/A
PROTECT (Retrophin)	IgAN	18+	Sparsentan	≥ 30
EFFICACY AND SAFETY IN IGA WITH RISK OF ESRD (NEFIGARD) (Calliditas)	IgAN	18+	Nefecon	≥ 45
EFFICACY AND SAFETY OF OMS721 IN IGAN PATIENTS (Omeros)	IgAN	18+	OMS721	≥ 30
ATACICEPT IN IGA NEPHROPATHY (EMD Serono)	IgAN	18+	Atacicept	N/A
THE DISCOVERY TRIAL (Apellis)	IgAN, C3G MN, Lupus Nephritis, MPGN	18+	APL-2	≥ 30
ACH-0144471 FOR C3G (Achillion)	C3G or MPGN	17-65	Ach-0144471	> 30

Visit KidneyHealthGateway.com to play your part in cutting-edge kidney research.



This is a living document and was last updated on 8/2/19.